{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:56:38Z","timestamp":1789887398281,"version":"4.0.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.lpm.2014.01.015","type":"journal-article","created":{"date-parts":[[2014,5,3]],"date-time":"2014-05-03T02:45:26Z","timestamp":1399085126000},"page":"742-755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["L\u2019endoth\u00e9line\u00a0: de la d\u00e9couverte aux avanc\u00e9es pharmacoth\u00e9rapeutiques"],"prefix":"10.1016","volume":"43","author":[{"given":"Vincent","family":"Richard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2014.01.015_bib0005","series-title":"Biologie et pathologie du coeur et des vaisseaux","first-page":"343","article-title":"Pathologie de l\u2019endoth\u00e9lium","author":"Boulanger","year":"2007"},{"key":"10.1016\/j.lpm.2014.01.015_bib0010","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1161\/01.CIR.91.5.1314","article-title":"Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo","volume":"91","author":"Joannides","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0015","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1161\/01.HYP.0000246672.72188.bd","article-title":"Crucial role of NO and endothelium-derived hyperpolarizing factor in human sustained conduit artery flow-mediated dilatation","volume":"48","author":"Bellien","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2014.01.015_bib0020","doi-asserted-by":"crossref","first-page":"C550","DOI":"10.1152\/ajpcell.1985.248.5.C550","article-title":"Characterization of a coronary vasoconstrictor produced by cultured endothelial cells","volume":"248","author":"Hickey","year":"1985","journal-title":"Am J Physiol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0025","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.lpm.2014.01.015_bib0030","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1073\/pnas.93.2.867","article-title":"Null mutation of endothelin receptor type B gene in spotting lethal rats causes aganglionic megacolon and white coat color","volume":"93","author":"Gariepy","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lpm.2014.01.015_bib0035","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nature06859","article-title":"Endothelins are vascular-derived axonal guidance cues for developing sympathetic neurons","volume":"452","author":"Makita","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.lpm.2014.01.015_bib0040","doi-asserted-by":"crossref","first-page":"14868","DOI":"10.1021\/bi961238w","article-title":"Interaction of endothelin-1\u00a0with cloned bovine ETA receptors: biochemical parameters and functional consequences","volume":"35","author":"Desmarets","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.lpm.2014.01.015_bib0045","doi-asserted-by":"crossref","first-page":"16066","DOI":"10.1016\/S0021-9258(18)41966-7","article-title":"Polar secretion of endothelin-1\u00a0by cultured endothelial cells","volume":"267","author":"Wagner","year":"1992","journal-title":"J Biol Chem"},{"issue":"Suppl 7","key":"10.1016\/j.lpm.2014.01.015_bib0050","doi-asserted-by":"crossref","first-page":"S362","DOI":"10.1097\/00005344-199100177-00103","article-title":"Differential pharmacological profile of endothelin-1\u00a0and its precursor, big endothelin","volume":"17","author":"Le Monnier de Gouville","year":"1991","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0055","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/cvr\/28.11.1613","article-title":"Why are circulating concentrations of endothelin-1\u00a0so low?","volume":"28","author":"Frelin","year":"1994","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.lpm.2014.01.015_bib0060","series-title":"The endothelin system in cardiopulmonary diseases","first-page":"33","article-title":"Is plasma endothelin a marker of endothelial dysfunction?","author":"Richard","year":"2004"},{"key":"10.1016\/j.lpm.2014.01.015_bib0065","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1172\/JCI114477","article-title":"Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide","volume":"85","author":"Boulanger","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lpm.2014.01.015_bib0070","doi-asserted-by":"crossref","first-page":"11938","DOI":"10.1016\/S0021-9258(17)32663-7","article-title":"Prostaglandin E2\u00a0and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells","volume":"269","author":"Prins","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.lpm.2014.01.015_bib0075","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1161\/01.CIR.91.3.771","article-title":"In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats","volume":"91","author":"Richard","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0080","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0008-6363(00)00264-9","article-title":"Pulmonary endothelinergic system in experimental congestive heart failure","volume":"49","author":"Lepailleur-Enouf","year":"2001","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.lpm.2014.01.015_bib0085","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1161\/01.CIR.101.23.2764","article-title":"Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failure","volume":"101","author":"Ben Driss","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0090","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1\u00a0in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.01.015_bib0095","doi-asserted-by":"crossref","first-page":"L258","DOI":"10.1152\/ajplung.2001.280.2.L258","article-title":"The NO donor molsidomine reduces endothelin-1\u00a0gene expression in chronic hypoxic rat lungs","volume":"280","author":"Blumberg","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0100","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1152\/jappl.1996.81.4.1510","article-title":"Pulmonary clearance of circulating endothelin-1\u00a0in dogs in vivo: exclusive role of ETB receptors","volume":"81","author":"Dupuis","year":"1996","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0105","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/01.CIR.94.7.1578","article-title":"Human pulmonary circulation is an important site for both clearance and production of endothelin-1","volume":"94","author":"Dupuis","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0110","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0002-8703(98)70276-5","article-title":"Reduced pulmonary clearance of endothelin-1\u00a0in pulmonary hypertension","volume":"135","author":"Dupuis","year":"1998","journal-title":"Am Heart J"},{"key":"10.1016\/j.lpm.2014.01.015_bib0115","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1161\/01.CIR.98.16.1684","article-title":"Reduced pulmonary clearance of endothelin-1\u00a0contributes to the increase of circulating levels in heart failure secondary to myocardial infarction","volume":"98","author":"Dupuis","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/01.CIR.100.1.5","article-title":"Endothelin-1\u00a0potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade","volume":"100","author":"Yang","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0125","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI116579","article-title":"Endothelin-1\u00a0is an autocrine\/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes","volume":"92","author":"Ito","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lpm.2014.01.015_bib0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/01.RES.69.1.209","article-title":"Endothelin-1\u00a0induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes","volume":"69","author":"Ito","year":"1991","journal-title":"Circ Res"},{"key":"10.1016\/j.lpm.2014.01.015_bib0135","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/01.CIR.0000105701.98663.D4","article-title":"Conditional cardiac overexpression of endothelin-1\u00a0induces inflammation and dilated cardiomyopathy in mice","volume":"109","author":"Yang","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0140","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1523-1747.2001.01256.x","article-title":"Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1","volume":"116","author":"Shi-Wen","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0145","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1165\/ajrcmb.11.4.7917311","article-title":"Increased levels of endothelin-1\u00a0in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro","volume":"11","author":"Cambrey","year":"1994","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1165\/ajrcmb.23.1.4030","article-title":"Pulmonary fibrosis and chronic lung inflammation in ET-1\u00a0transgenic mice","volume":"23","author":"Hocher","year":"2000","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0155","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1476-5381.1995.tb15868.x","article-title":"Acute pro-inflammatory actions of endothelin-1\u00a0in the guinea-pig lung: involvement of ETA and ETB receptors","volume":"115","author":"Filep","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0160","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s003950050170","article-title":"Endothelin-1\u00a0induces interleukin-6\u00a0release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells","volume":"95","author":"Browatzki","year":"2000","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0165","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1472-8206.2008.00634.x","article-title":"Role of endogenous endothelin in endothelial dysfunction in murine model of systemic sclerosis: tight skin mice 1","volume":"22","author":"Richard","year":"2008","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0170","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/FJC.0b013e31813c6cc3","article-title":"Mechanisms of ET-1-induced endothelial dysfunction","volume":"50","author":"Iglarz","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0175","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/01.HYP.19.2.131","article-title":"Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries","volume":"19","author":"Dohi","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2014.01.015_bib0180","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1472-8206.2000.tb00397.x","article-title":"receptor blockade unmasks a depressor response to endothelin antagonists in rats","volume":"14","author":"Richard","year":"2000","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0185","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/01.HYP.27.5.1153","article-title":"Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats","volume":"27","author":"Belloni","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2014.01.015_bib0190","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1161\/HYPERTENSIONAHA.110.163972","article-title":"Endothelin-converting enzyme\/neutral endopeptidase inhibitor SLV338\u00a0prevents hypertensive cardiac remodeling in a blood pressure-independent manner","volume":"57","author":"Kalk","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2014.01.015_bib0195","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00005344-200404000-00003","article-title":"Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure","volume":"43","author":"Mulder","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0200","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0022-3565(25)22357-6","article-title":"Pharmacological characterization of bosentan, a new potent orally active nonpe-ptide endothelin receptor antagonist","volume":"270","author":"Clozel","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.lpm.2014.01.015_bib0205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1527-3466.2006.00063.x","article-title":"Ambrisentan, a non-peptide endothelin receptor antagonist","volume":"24","author":"Vatter","year":"2006","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.lpm.2014.01.015_bib0210","doi-asserted-by":"crossref","first-page":"F144","DOI":"10.1152\/ajprenal.2001.281.1.F144","article-title":"Evidence for endothelin involvement in the response to high salt","volume":"281","author":"Pollock","year":"2001","journal-title":"Am J Physiol Renal physiol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0215","doi-asserted-by":"crossref","first-page":"H1555","DOI":"10.1152\/ajpheart.00346.2002","article-title":"Hypertension induced by blockade of ET(B) receptors in conscious nonhuman primates: role of ET(A) receptors","volume":"283","author":"Reinhart","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0220","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/01.CIR.98.21.2262","article-title":"Short-term oral endothelin receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure","volume":"98","author":"Sutsch","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0225","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00004872-200018030-00006","article-title":"Receptor- and non-receptor-mediated clearance of big endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade","volume":"18","author":"Burkhardt","year":"2000","journal-title":"J Hypertens"},{"key":"10.1016\/j.lpm.2014.01.015_bib0230","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0735-1097(00)00649-5","article-title":"Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure ET 003\u00a0Investigators","volume":"35","author":"Spieker","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0235","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1161\/01.CIR.0000087596.01416.2F","article-title":"Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow","volume":"108","author":"Black","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0240","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/hc0902.105719","article-title":"Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension","volume":"105","author":"Bauer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0245","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1161\/01.HYP.33.3.816","article-title":"Endothelin system-dependent cardiac remodeling in renovascular hypertension","volume":"33","author":"Hocher","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2014.01.015_bib0250","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/01.CIR.102.5.491","article-title":"Selective endothelin-A versus combined endothelin-A\/endothelin-B receptor blockade in rat chronic heart failure","volume":"102","author":"Mulder","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0255","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1161\/01.CIR.0000027138.07524.38","article-title":"Long-term survival and hemodynamics after endothelin-a receptor antagonism and angiotensin-converting enzyme inhibition in rats with chronic heart failure: monotherapy versus combination therapy","volume":"106","author":"Mulder","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0260","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1161\/01.CIR.96.6.1976","article-title":"Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling","volume":"96","author":"Mulder","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0265","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/01.CIR.103.2.314","article-title":"Effectiveness of a nonselective ET(A\/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension","volume":"103","author":"Jasmin","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0270","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0008-6363(98)00159-X","article-title":"Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure","volume":"39","author":"Mulder","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.lpm.2014.01.015_bib0275","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1161\/01.CIR.90.5.2510","article-title":"Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan)","volume":"90","author":"Teerlink","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0280","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/384353a0","article-title":"Inhibition of myocardial endothelin pathway improves long-term survival in heart failure","volume":"384","author":"Sakai","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.lpm.2014.01.015_bib0285","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(95)91504-4","article-title":"Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure","volume":"346","author":"Kiowski","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2014.01.015_bib0290","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0735-1097(03)00556-4","article-title":"Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure","volume":"42","author":"Torre-Amione","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0295","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(05)77807-7","article-title":"Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure","volume":"352","author":"Cowburn","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2014.01.015_bib0300","first-page":"696","article-title":"Clinical trials of endothelin antagonists in heart failure: a question of dose?","volume":"231","author":"Kelland","year":"2006","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.lpm.2014.01.015_bib0305","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1152\/jappl.1995.79.6.2122","article-title":"Endothelin receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats","volume":"79","author":"Chen","year":"1995","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0310","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/00365510701673375","article-title":"Effects of selective and unselective endothelin receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension","volume":"68","author":"Schroll","year":"2008","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.lpm.2014.01.015_bib0315","first-page":"H828","article-title":"Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats","volume":"268","author":"Eddahibi","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0320","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.01.015_bib0325","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Galie","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2014.01.015_bib0330","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2014.01.015_bib0335","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1\u00a0and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0340","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension","volume":"54","author":"Oudiz","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0345","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.amjcard.2011.03.037","article-title":"Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension","volume":"108","author":"Klinger","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0350","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2014.01.015_bib0355","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension","volume":"25","author":"McLaughlin","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.01.015_bib0360","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2005.01.066","article-title":"Effects of long-term bosentan in children with pulmonary arterial hypertension","volume":"46","author":"Rosenzweig","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0365","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/CIRCULATIONAHA.109.883876","article-title":"Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension","volume":"121","author":"Dimopoulos","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2014.01.015_bib0370","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1183\/09059180.00007810","article-title":"Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management","volume":"19","author":"Hachulla","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.01.015_bib0375","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1136\/ard.2007.079921","article-title":"Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases","volume":"67","author":"Denton","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2014.01.015_bib0380","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2014.01.015_bib0385","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2014.01.015_bib0390","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1021\/jm3009103","article-title":"The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N\u2032-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist","volume":"55","author":"Bolli","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.lpm.2014.01.015_bib0395","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.108.142976","article-title":"Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist","volume":"327","author":"Iglarz","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.lpm.2014.01.015_bib0400","first-page":"A6445","article-title":"Optimization of tissue-targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension","volume":"183","author":"Iglarz","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2014.01.015_bib0405","doi-asserted-by":"crossref","first-page":"e47662","DOI":"10.1371\/journal.pone.0047662","article-title":"Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells","volume":"7","author":"Gatfield","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lpm.2014.01.015_bib0410","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/00498254.2012.664665","article-title":"Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans","volume":"42","author":"Bruderer","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1016\/j.lpm.2014.01.015_bib0415","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1208\/s12248-011-9316-3","article-title":"Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist","volume":"14","author":"Bruderer","year":"2012","journal-title":"AAPS J"},{"key":"10.1016\/j.lpm.2014.01.015_bib0420","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00228-011-1043-2","article-title":"entry-into-humans study with a new endothelin receptor antagonist","volume":"67","author":"Sidharta","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0425","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.152","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects","author":"Sidharta","year":"2013","journal-title":"J Clinical Pharmacol"},{"key":"10.1016\/j.lpm.2014.01.015_bib0430","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mcp.2001.114667","article-title":"The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions","volume":"69","author":"Fattinger","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.lpm.2014.01.015_bib0435","first-page":"1066","article-title":"Macitentan a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis","volume":"11","author":"Raja","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.lpm.2014.01.015_bib0440","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2014.01.015_bib0445","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1183\/09031936.00104612","article-title":"Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial","volume":"42","author":"Raghu","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2014.01.015_bib0450","first-page":"185","article-title":"Lack of clinically relevant pharmacokinetic interactions between the dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects","author":"Sidharta","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2014.01.015_bib0455","first-page":"P950","article-title":"Lack of relevant pharmacokinetic and pharmacodynamic interactions between the new dual endothelin receptor antagonist macitentan and warfarin in healthy subjects","volume":"185","author":"Sidharta","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2014.01.015_bib0460","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40262-013-0063-8","article-title":"Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects","volume":"52","author":"Atsmon","year":"2013","journal-title":"Clinical pharmacokinetics"},{"key":"10.1016\/j.lpm.2014.01.015_bib0465","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1046\/j.1523-1755.2000.00838.x","article-title":"Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A","volume":"57","author":"Binet","year":"2000","journal-title":"Kidney Int"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498214001900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498214001900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T17:24:39Z","timestamp":1746206679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498214001900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":93,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0755498214001900"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2014.01.015","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L\u2019endoth\u00e9line\u00a0: de la d\u00e9couverte aux avanc\u00e9es pharmacoth\u00e9rapeutiques","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2014.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}